$ALZN
Alzamend Neuro, Inc.

2024 Q4 Form 10-Q Financial Statement

#000121465924020264 Filed on December 11, 2024

View on sec.gov

Income Statement

Concept 2024 Q4
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $311.1K
YoY Change -84.42%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.358M
YoY Change -53.2%
Operating Profit -$1.358M
YoY Change -53.2%
Interest Expense $3.495K
YoY Change -18.93%
% of Operating Profit
Other Income/Expense, Net -$3.495K
YoY Change -18.93%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$1.415M
YoY Change -51.3%
Net Earnings / Revenue
Basic Earnings Per Share -$0.40
Diluted Earnings Per Share -$0.40
COMMON SHARES
Basic Shares Outstanding 3.532M shares
Diluted Shares Outstanding 3.532M shares

Balance Sheet

Concept 2024 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $4.093M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $4.767M
YoY Change 509.65%
LONG-TERM ASSETS
Property, Plant & Equipment $241.0K
YoY Change 19.46%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $241.0K
YoY Change 19.46%
TOTAL ASSETS
Total Short-Term Assets $4.767M
Total Long-Term Assets $241.0K
Total Assets $5.008M
YoY Change 409.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.255M
YoY Change -65.77%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities
Total Long-Term Liabilities
Total Liabilities $1.255M
YoY Change -65.77%
SHAREHOLDERS EQUITY
Retained Earnings -$56.41M
YoY Change 11.69%
Common Stock $523.00
YoY Change -19.17%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.753M
YoY Change
Total Liabilities & Shareholders Equity $5.008M
YoY Change 409.12%

Cashflow Statement

Concept 2024 Q4
OPERATING ACTIVITIES
Net Income -$1.415M
YoY Change -51.3%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Address City Or Town
EntityAddressCityOrTown
Atlanta
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4093073 usd
CY2024Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
673669 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
79194 usd
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Document Period End Date
DocumentPeriodEndDate
2024-10-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--04-30
CY2024Q4 us-gaap Notes Payable Current
NotesPayableCurrent
usd
dei Document Type
DocumentType
10-Q
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
5432797 shares
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
79194 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
176346 usd
CY2024Q4 us-gaap Assets
Assets
5007718 usd
CY2024Q2 us-gaap Assets
Assets
631588 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2925059 usd
CY2024Q2 us-gaap Notes Payable Current
NotesPayableCurrent
300714 usd
CY2024Q4 us-gaap Liabilities
Liabilities
1254750 usd
CY2024Q2 us-gaap Liabilities
Liabilities
3225773 usd
CY2024Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2024Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5231254 shares
CY2024Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5231254 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
687999 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
687999 shares
CY2024Q4 us-gaap Common Stock Value
CommonStockValue
523 usd
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
69 usd
CY2024Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
60162478 usd
CY2024Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-56410033 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54020408 usd
CY2024Q4 us-gaap Stockholders Equity
StockholdersEquity
3752968 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-2594185 usd
CY2024Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5007718 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
631588 usd
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Entity Central Index Key
EntityCentralIndexKey
0001677077
CY2023Q4 alzm Dividends On Preferred Shares
DividendsOnPreferredShares
usd
alzm Dividends On Preferred Shares
DividendsOnPreferredShares
usd
CY2024Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
CY2024Q4 alzm Conversion Of Preferred Stock To Common Stock
ConversionOfPreferredStockToCommonStock
usd
CY2023Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
CY2023Q4 alzm Subscription Receivable Payment Received
SubscriptionReceivablePaymentReceived
usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
alzm Conversion Of Preferred Stock To Common Stock
ConversionOfPreferredStockToCommonStock
usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
alzm Subscription Receivable Payment Received
SubscriptionReceivablePaymentReceived
usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
usd
alzm Increase Decrease In Prepaid Expenses Related Party
IncreaseDecreaseInPrepaidExpensesRelatedParty
usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
usd
alzm Conversion Of Series Convertible Preferred Stock
ConversionOfSeriesConvertiblePreferredStock
usd
alzm Fair Value Of Warrants Issued In Connection With Series Convertible Preferred Stock
FairValueOfWarrantsIssuedInConnectionWithSeriesConvertiblePreferredStock
usd
alzm Conversion Of Note Payable And Accrued Interest Into Series B Convertible Preferred Stock
ConversionOfNotePayableAndAccruedInterestIntoSeriesBConvertiblePreferredStock
usd
CY2024Q2 alzm Prepaid Clinical Trial Expenses
PrepaidClinicalTrialExpenses
usd
alzm Shares Available For Grant Options Granted
SharesAvailableForGrantOptionsGranted
shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
alzm Shares Available For Grant Options Exercised
SharesAvailableForGrantOptionsExercised
shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40483
dei Entity Registrant Name
EntityRegistrantName
ALZAMEND NEURO, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-1822909
dei Entity Address Address Line1
EntityAddressAddressLine1
3480 Peachtree Road NE
dei Entity Address Address Line2
EntityAddressAddressLine2
Second Floor Suite 103
dei Entity Address State Or Province
EntityAddressStateOrProvince
GA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
30326
dei City Area Code
CityAreaCode
844
dei Local Phone Number
LocalPhoneNumber
722-6303
dei Trading Symbol
TradingSymbol
ALZN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
376048 usd
CY2024Q4 us-gaap Assets Current
AssetsCurrent
4766742 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
455242 usd
CY2024Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
240976 usd
CY2024Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1254750 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
51426154 usd
CY2024Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
311088 usd
CY2023Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1996783 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
517659 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4362920 usd
CY2024Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1046980 usd
CY2023Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
904939 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1802814 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2064732 usd
CY2024Q4 us-gaap Operating Expenses
OperatingExpenses
1358068 usd
CY2023Q4 us-gaap Operating Expenses
OperatingExpenses
2901722 usd
us-gaap Operating Expenses
OperatingExpenses
2320473 usd
us-gaap Operating Expenses
OperatingExpenses
6427652 usd
CY2024Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-1358068 usd
CY2023Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-2901722 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2320473 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6427652 usd
CY2024Q4 us-gaap Interest Expense
InterestExpense
3495 usd
CY2023Q4 us-gaap Interest Expense
InterestExpense
4311 usd
us-gaap Interest Expense
InterestExpense
15501 usd
us-gaap Interest Expense
InterestExpense
6147 usd
CY2024Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3495 usd
CY2023Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4311 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-15501 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6147 usd
CY2024Q4 us-gaap Profit Loss
ProfitLoss
-1361563 usd
CY2023Q4 us-gaap Profit Loss
ProfitLoss
-2906033 usd
us-gaap Profit Loss
ProfitLoss
-2335974 usd
us-gaap Profit Loss
ProfitLoss
-6433799 usd
CY2024Q4 alzm Dividends On Preferred Shares
DividendsOnPreferredShares
53651 usd
alzm Dividends On Preferred Shares
DividendsOnPreferredShares
53651 usd
CY2024Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1415214 usd
CY2023Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2906033 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2389625 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6433799 usd
CY2024Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
CY2024Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.43
CY2023Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.43
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.11
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.80
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.80
CY2024Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3531702 shares
CY2024Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3531702 shares
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
656378 shares
CY2023Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
656378 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2154761 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2154761 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
656323 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
656323 shares
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1212319 usd
CY2024Q4 alzm Issuance Of Common Stock For Cash Net Of Issuance Costs
IssuanceOfCommonStockForCashNetOfIssuanceCosts
1174224 usd
CY2024Q4 alzm Issuance Of Preferred Stock For Cash Net Of Issuance Costs
IssuanceOfPreferredStockForCashNetOfIssuanceCosts
5125000 usd
CY2024Q4 alzm Stockbased Compensation To Employees And Consultants
StockbasedCompensationToEmployeesAndConsultants
81277 usd
CY2024Q4 us-gaap Net Income Loss
NetIncomeLoss
-1415214 usd
CY2024Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3752968 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-112883 usd
CY2023Q4 alzm Issuance Of Common Stock For Cash Net Of Issuance Costs
IssuanceOfCommonStockForCashNetOfIssuanceCosts
18087 usd
CY2023Q4 alzm Stockbased Compensation To Employees And Consultants
StockbasedCompensationToEmployeesAndConsultants
318336 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-2906033 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2682493 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2594185 usd
alzm Issuance Of Common Stock For Cash Net Of Issuance Costs
IssuanceOfCommonStockForCashNetOfIssuanceCosts
1174224 usd
alzm Issuance Of Preferred Stock For Cash Net Of Issuance Costs
IssuanceOfPreferredStockForCashNetOfIssuanceCosts
7088644 usd
alzm Conversion Of Note Payable And Interest To Preferred Stock
ConversionOfNotePayableAndInterestToPreferredStock
311356 usd
alzm Stockbased Compensation To Employees And Consultants
StockbasedCompensationToEmployeesAndConsultants
162554 usd
us-gaap Net Income Loss
NetIncomeLoss
-2389625 usd
CY2024Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3752968 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3045503 usd
alzm Issuance Of Common Stock For Cash Net Of Issuance Costs
IssuanceOfCommonStockForCashNetOfIssuanceCosts
18087 usd
alzm Stockbased Compensation To Employees And Consultants
StockbasedCompensationToEmployeesAndConsultants
687716 usd
us-gaap Net Income Loss
NetIncomeLoss
-6433799 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2682493 usd
us-gaap Net Income Loss
NetIncomeLoss
-2389625 usd
us-gaap Net Income Loss
NetIncomeLoss
-6433799 usd
us-gaap Depreciation
Depreciation
25370 usd
us-gaap Depreciation
Depreciation
25370 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
9286 usd
us-gaap Share Based Compensation
ShareBasedCompensation
162554 usd
us-gaap Share Based Compensation
ShareBasedCompensation
687716 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
594475 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
134213 usd
alzm Increase Decrease In Prepaid Expenses Related Party
IncreaseDecreaseInPrepaidExpensesRelatedParty
-247334 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1668953 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
795968 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4455843 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4811624 usd
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
90000 usd
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
147243 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-90000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-147243 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1174224 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
18087 usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
7088644 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8262868 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18087 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
3717025 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-4940780 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
376048 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5140859 usd
CY2024Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4093073 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
200079 usd
alzm Conversion Of Series Convertible Preferred Stock
ConversionOfSeriesConvertiblePreferredStock
7120133 usd
alzm Fair Value Of Warrants Issued In Connection With Series Convertible Preferred Stock
FairValueOfWarrantsIssuedInConnectionWithSeriesConvertiblePreferredStock
1635489 usd
alzm Conversion Of Note Payable And Accrued Interest Into Series B Convertible Preferred Stock
ConversionOfNotePayableAndAccruedInterestIntoSeriesBConvertiblePreferredStock
311356 usd
CY2024Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q4 us-gaap Cash
Cash
4100000 usd
CY2024Q4 alzm Working Capital Deficiency
WorkingCapitalDeficiency
3500000 usd
CY2024Q4 us-gaap Retained Earnings Appropriated
RetainedEarningsAppropriated
56400000 usd
CY2024Q4 us-gaap Stockholders Equity Before Treasury Stock
StockholdersEquityBeforeTreasuryStock
3800000 usd
CY2024Q4 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
1400000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
2400000 usd
alzm Cash Used In Operating Activities
CashUsedInOperatingActivities
4500000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_844_eus-gaap--UseOfEstimates_zGb9vUnsiA07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_86A_zMK0CxrxZTnj">Accounting Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.8pt">The preparation of condensed financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting period. The Company’s significant accounting policies that involve significant judgment and estimates include stock-based compensation, warrant valuation, and valuation of deferred income taxes. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2024Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2024Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2024Q4 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P5Y
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
990533 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
188969 shares
CY2024Q4 alzm Prepaid Clinical Trial Expenses
PrepaidClinicalTrialExpenses
490911 usd
CY2024Q4 us-gaap Prepaid Insurance
PrepaidInsurance
163332 usd
CY2024Q2 us-gaap Prepaid Insurance
PrepaidInsurance
60523 usd
CY2024Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
19426 usd
CY2024Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
18671 usd
CY2024Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
673669 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
62000 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
98000 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
178.12
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y2M19D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
70500 usd
alzm Shares Available For Grant Options Expired
SharesAvailableForGrantOptionsExpired
3333 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
3333 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
150.00
CY2024Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
65333 shares
CY2024Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
94667 shares
CY2024Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
179.11
alzm Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm
P4Y10M24D
CY2024Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
15100 usd
CY2024Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
88001 shares
CY2024Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
179.39
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P4Y7M24D
CY2024Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
15100 usd
CY2024Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
87043 shares
CY2024Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
178.87
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y7M17D
CY2024Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
15100 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
167 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
375.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
83 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
375.00
CY2024Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
84 shares
CY2024Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
375.00
CY2024Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
81277 usd
CY2023Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
175733 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
162554 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
687716 usd
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
240449 shares
CY2024Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
67.45
alzm Class Of Warrant Or Right Outstanding Granted
ClassOfWarrantOrRightOutstandingGranted
640000 shares
alzm Weighted Average Exercises Price Granted
WeightedAverageExercisesPriceGranted
12.50
alzm Class Of Warrant Or Right Outstanding Cancelledexpired
ClassOfWarrantOrRightOutstandingCancelledexpired
-6999 shares
alzm Weighted Average Exercise Price Cancelledexpired
WeightedAverageExercisePriceCancelledexpired
320.28
CY2024Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
873450 shares
CY2024Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
24.35
CY2024Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
755888 shares
us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
1200000 usd
CY2024Q4 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
649.5363 shares
CY2024Q4 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
3613951 shares
us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
712.0133 shares
us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
3787284 shares
CY2024Q4 alzm Origination Fees
OriginationFees
275000 usd
alzm Origination Fees
OriginationFees
400000 usd
CY2024Q4 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
201543 shares
CY2024Q4 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
280000 usd
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001214659-24-020264-index-headers.html Edgar Link pending
0001214659-24-020264-index.html Edgar Link pending
0001214659-24-020264.txt Edgar Link pending
0001214659-24-020264-xbrl.zip Edgar Link pending
alzm-20241031.xsd Edgar Link pending
ex31_1.htm Edgar Link pending
ex31_2.htm Edgar Link pending
ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
p12624510q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
alzm-20241031_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
alzm-20241031_cal.xml Edgar Link unprocessable
alzm-20241031_lab.xml Edgar Link unprocessable
alzm-20241031_def.xml Edgar Link unprocessable
p12624510q_htm.xml Edgar Link completed
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending